bluebird bio, Inc.

BLUE

US09609G1004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:28:29 17/07/2024 BST			5-day change	1st Jan Change
1.205 ^USD	-10.74%		+16.35%	-12.32%

06-12	Transcript : Bluebird bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 11:20 AM
05-29	Bluebird bio, Inc. Announces Executive Changes, Effective from June 10, 2024	CI

Certain Stock Options of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2017.

January 19, 2017

Certain shares of bluebird bio, Inc.'s Stock Options are subject to a Lock-Up Agreement Ending on 20-JAN-2017. These shares will be under lockup for 45 days starting from 6-DEC-2016 to 20-JAN-2017.

Latest news about bluebird bio, Inc.

Transcript : Bluebird bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 11:20 AM	06-12
Bluebird bio, Inc. Announces Executive Changes, Effective from June 10, 2024	05-29	CI
Bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024	05-29	CI
Transcript : Bluebird bio, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM	05-16
Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy	05-06	CI
Bluebird Bio, Inc. Enters into an Amendment to Its Loan and Security Agreement	05-03	CI
Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report	04-26	MT
Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	03-27	MT
Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating	03-27	MT
Bluebird bio to Restate Financial Statements; Shares Fall	03-26	MT
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating	03-26	MT
Transcript : Bluebird bio, Inc., Q4 2023 Earnings Call, Mar 26, 2024	03-26
Gene therapy maker bluebird to restate 2022 financials after accounting error	03-26	RE
Wedbush Adjusts bluebird bio's Price Target to $1.68 From $3, Maintains Neutral Rating	03-19	MT
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon	03-18	MT
Sector Update: Health Care	03-18	MT
Bluebird bio Secures $175 Million Term Loan Facility	03-18	MT
Bluebird bio, Inc. Enters into $175 Million Five-Year, Term Loan Facility with Hercules Capital, Inc	03-18	CI
Bluebird bio, Inc. announced that it expects to receive $175 million in funding	03-17	CI
Bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Biotechnology Select Industry Index	03-17	CI
Bluebird bio Signs Medicaid Agreement for Sickle Cell Disease Therapy with Michigan State	03-11	MT
Bluebird bio, Inc. Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy	03-11	CI
HSBC Adjusts bluebird bio's Price Target to $1.02 From $2.31, Keeps Reduce Rating	03-05	MT
Certain Pre-Funded Warrants of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	02-02	CI

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for bluebird bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.35 USD

Average target price

3.574 USD

Spread / Average Target

+164.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BLUEBIRD BIO, INC.	-12.32%	260M
VERTEX PHARMACEUTICALS INCORPORATED	+18.04%	126B
REGENERON PHARMACEUTICALS, INC.	+22.82%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.68%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-15.69%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.85%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.56%	14.08B

Bio Therapeutic Drugs

bluebird bio, Inc.

Equities

BLUE

US09609G1004

Biotechnology & Medical Research

Certain Stock Options of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2017.

Latest news about bluebird bio, Inc.

Chart bluebird bio, Inc.

Company Profile

Income Statement Evolution

Ratings for bluebird bio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs